RE: Patent Office Update18 Jul 2025 09:54
No idea what Genflow could be worth Bunsen, but Lilly have just paid this for 1 gene therapy programme, when Genflow have 5 with a further 3 compound variations on the go:
Eli Lilly is acquiring Verve Therapeutics for approximately $1.3 billion, expanding its cardiovascular disease pipeline with Verve's gene editing therapies. The deal includes an upfront cash payment of $10.50 per share, totaling around $1 billion, plus a contingent value right (CVR) potentially worth an additional $3.00 per share, according to Eli Lilly and Company. This acquisition will give Lilly access to Verve's lead program, VERVE-102, a potential first-in-class in vivo gene editing treatment targeting PCSK9, a gene associated with cholesterol levels and cardiovascular health.